Literature DB >> 17307320

Evaluation of ADL in patients with Hunter disease using FIM score.

Tomomi Kato1, Zenichiro Kato, Izumi Kuratsubo, Tetsuo Ota, Tadao Orii, Naomi Kondo, Yasuyuki Suzuki.   

Abstract

MPS type II (Hunter disease) results from deficiency of the lysosomal enzyme iduronate-2-sulfate sulfatase. Two forms of the disease have been recognized, based on absence or presence of progressive intellectual deterioration. This study aimed to assess activities of daily life (ADL) in 27 Hunter disease-affected Japanese patients, using a modified version of the functional independence measure (FIM). Scores of ADL for patients with a severe phenotype were significantly lower than those of control children. Total scores were highest around 5-7 years old, then progressively decreased, and scores <40 were obtained with patients aged 9 years or more. In contrast to motor scores, cognitive scores decreased rapidly, generally reaching a minimum score at around 7 years old. On the other hand, in children with attenuated phenotype, total scores increased progressively with age similar to control children. Two children who had the highest grades at elementary school showed maximum scores. However, all adult patients did not show maximum total scores, and 3 of 4 patients over 25 years old showed decreasing scores. Two children and two adults showed significant lower scores compared with other patients, suggesting an intermediate form from the view of ADL. This study elucidated the precise clinical state of Hunter disease with distinct numerical scores, in addition to previously described narrative data. To maintain the QOL of the patients better, they and their family need to know what specific difficulties they encounter, in which period they encounter them, and what support can fix them. Further ADL investigations with larger populations and/or long-term sequential examination could help the patients and family to understand them well.

Entities:  

Mesh:

Year:  2007        PMID: 17307320     DOI: 10.1016/j.braindev.2006.08.015

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  12 in total

1.  Activity of daily living for Morquio A syndrome.

Authors:  Eriko Yasuda; Yasuyuki Suzuki; Tsutomu Shimada; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Li Xie; Freeman Miller; Tariq Rahman; Heidi H Kecskemethy; Kyoko Nagao; Thierry Morlet; Thomas H Shaffer; Yasutsugu Chinen; Hiromasa Yabe; Akemi Tanaka; Haruo Shintaku; Kenji E Orii; Koji O Orii; Robert W Mason; Adriana M Montaño; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-04-25       Impact factor: 4.797

2.  Developmental changes of radiological findings in Fukuyama-type congenital muscular dystrophy.

Authors:  Zenichiro Kato; Masahiro Morimoto; Kenji E Orii; Tomomi Kato; Naomi Kondo
Journal:  Pediatr Radiol       Date:  2010-06-23

3.  Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.

Authors:  Julian Tanjuakio; Yasuyuki Suzuki; Pravin Patel; Eriko Yasuda; Francyne Kubaski; Akemi Tanaka; Hiromasa Yabe; Robert W Mason; Adriana M Montaño; Kenji E Orii; Koji O Orii; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2014-11-08       Impact factor: 4.797

Review 4.  Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.

Authors:  S Al Sawaf; E Mayatepek; B Hoffmann
Journal:  J Inherit Metab Dis       Date:  2008-07-13       Impact factor: 4.982

5.  Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.

Authors:  Bianca Link; Louise Lapagesse de Camargo Pinto; Roberto Giugliani; James Edmond Wraith; Nathalie Guffon; Elke Eich; Michael Beck
Journal:  Orthop Rev (Pavia)       Date:  2010-09-23

6.  Serum levels of vitamin A and 25-hydroxyvitamin D3 (25OHD3) as reflectors of pulmonary function and quality of life (QOL) in children with stable asthma: A case-control study.

Authors:  Ya-Jie Bai; Ru-Jun Dai
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

7.  FUNCTIONAL INDEPENDENCE OF PEDIATRIC PATIENTS WITH MUCOPOLYSACCHARIDOSES.

Authors:  Paloma Silva Lopes; Diógenes Pires Serra; Marcos Antônio Almeida Matos
Journal:  Acta Ortop Bras       Date:  2019 Jul-Aug       Impact factor: 0.513

8.  A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II.

Authors:  Elsa G Shapiro; Kyle Rudser; Alia Ahmed; Robert D Steiner; Kathleen A Delaney; Brianna Yund; Kelly King; Alicia Kunin-Batson; Julie Eisengart; Chester B Whitley
Journal:  Mol Genet Metab Rep       Date:  2016-04-01

Review 9.  Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues.

Authors:  Christian J Hendriksz; Kenneth I Berger; Christina Lampe; Susanne G Kircher; Paul J Orchard; Rebecca Southall; Sarah Long; Stephen Sande; Jeffrey I Gold
Journal:  Orphanet J Rare Dis       Date:  2016-08-26       Impact factor: 4.123

10.  Assessment of Activity of Daily Life in Mucopolysaccharidosis Type II Patients with Hematopoietic Stem Cell Transplantation.

Authors:  Yasuyuki Suzuki; Madeleine Taylor; Kenji Orii; Toshiyuki Fukao; Tadao Orii; Shunji Tomatsu
Journal:  Diagnostics (Basel)       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.